Sensitive detection of glucagon aggregation using amyloid fibril‐specific antibodies
dc.contributor.author | Stimple, Samuel D. | |
dc.contributor.author | Kalyoncu, Sibel | |
dc.contributor.author | Desai, Alec A. | |
dc.contributor.author | Mogensen, Jesper E. | |
dc.contributor.author | Spang, Lotte T. | |
dc.contributor.author | Asgreen, Désirée J. | |
dc.contributor.author | Staby, Arne | |
dc.contributor.author | Tessier, Peter M. | |
dc.date.accessioned | 2019-08-09T17:15:51Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2019-08-09T17:15:51Z | |
dc.date.issued | 2019-08 | |
dc.identifier.citation | Stimple, Samuel D.; Kalyoncu, Sibel; Desai, Alec A.; Mogensen, Jesper E.; Spang, Lotte T.; Asgreen, Désirée J. ; Staby, Arne; Tessier, Peter M. (2019). "Sensitive detection of glucagon aggregation using amyloid fibril‐specific antibodies." Biotechnology and Bioengineering 116(8): 1868-1877. | |
dc.identifier.issn | 0006-3592 | |
dc.identifier.issn | 1097-0290 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/150615 | |
dc.description.abstract | Sensitive detection of protein aggregates is important for evaluating the quality of biopharmaceuticals and detecting misfolded proteins in several neurodegenerative diseases. However, it is challenging to detect extremely low concentrations (<10 ppm) of aggregated protein in the presence of high concentrations of soluble protein. Glucagon, a peptide hormone used in the treatment of extreme hypoglycemia, is aggregation‐prone and forms amyloid fibrils. Detection of glucagon fibrils using conformation‐specific antibodies is an attractive approach for identifying such aggregates during process and formulation development. Therefore, we have used yeast surface display and magnetic‐activated cell sorting to sort single‐chain antibody libraries to identify antibody variants with high conformational specificity for glucagon fibrils. Notably, we find several high‐affinity antibodies that display excellent selectivity for glucagon fibrils, and we have integrated these antibodies into a sensitive immunoassay. Surprisingly, the sensitivity of our assay—which involves direct (nonantibody mediated) glucagon immobilization in microtiter plates—can be significantly enhanced by pretreating the microtiter plates with various types of globular proteins before glucagon immobilization. Moreover, increased total concentrations of glucagon peptide also significantly improve the sensitivity of our assay, which appears to be due to the strong seeding activity of immobilized fibrils at high glucagon concentrations. Our final assay is highly sensitive (fibril detection limit of ~0.5–1 ppm) and is >20 times more sensitive than detection using a conventional, amyloid‐specific fluorescent dye (Thioflavin T). We expect that this type of sensitive immunoassay can be readily integrated into the drug development process to improve the generation of safe and potent peptide therapeutics.Sensitive detection of protein aggregates is important for evaluating the quality of biopharmaceuticals and detecting misfolded proteins in several neurodegenerative diseases. However, it is challenging to detect extremely low concentrations (<10 ppm) of aggregated protein in the presence of high concentrations of soluble protein. Glucagon, a peptide hormone used in the treatment of extreme hypoglycemia, is aggregation‐prone and forms amyloid fibrils. Conformation‐specific antibodies were generated that recognize glucagon fibrils in a highly selective manner, and these antibodies were integrated into an ELISA method that is >20 times more sensitive than conventional methods for detecting glucagon fibrils. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | protein | |
dc.subject.other | antibody | |
dc.subject.other | conformation | |
dc.subject.other | directed evolution | |
dc.subject.other | aggregate | |
dc.title | Sensitive detection of glucagon aggregation using amyloid fibril‐specific antibodies | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbsecondlevel | Biological Chemistry | |
dc.subject.hlbsecondlevel | Ecology and Evolutionary Biology | |
dc.subject.hlbsecondlevel | Mathematics | |
dc.subject.hlbsecondlevel | Natural Resources and Environment | |
dc.subject.hlbsecondlevel | Statistics and Numeric Data | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.subject.hlbtoplevel | Science | |
dc.subject.hlbtoplevel | Social Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/150615/1/bit26994_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/150615/2/bit26994.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/150615/3/bit26994-sup-0001-Supporting_Information__submission_.pdf | |
dc.identifier.doi | 10.1002/bit.26994 | |
dc.identifier.source | Biotechnology and Bioengineering | |
dc.identifier.citedreference | Pedersen, J. S., & Otzen, D. E. ( 2008 ). Amyloid‐a state in many guises: Survival of the fittest fibril fold. Protein Science, 17 ( 1 ), 2 – 10. https://doi.org/10.1110/ps.073127808 | |
dc.identifier.citedreference | Perchiacca, J. M., & Tessier, P. M. ( 2012 ). Engineering aggregation‐resistant antibodies. Annual Review of Chemical and Biomolecular Engineering, 3, 263 – 286. https://doi.org/10.1146/annurev‐chembioeng‐062011‐081052 | |
dc.identifier.citedreference | Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., … Glabe, C. G. ( 2007 ). Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration, 2, 18. https://doi.org/10.1186/1750‐1326‐2‐18 | |
dc.identifier.citedreference | Lowe, D., Dudgeon, K., Rouet, R., Schofield, P., Jermutus, L., & Christ, D. ( 2011 ). Aggregation, stability, and formulation of human antibody therapeutics. Advances in Protein Chemistry and Structural Biology, 84, 41 – 61. https://doi.org/10.1016/B978‐0‐12‐386483‐3.00004‐5 | |
dc.identifier.citedreference | Oliveira, C. L., Behrens, M. A., Pedersen, J. S., Erlacher, K., Otzen, D., & Pedersen, J. S. ( 2009 ). A SAXS study of glucagon fibrillation. Journal of Molecular Biology, 387 ( 1 ), 147 – 161. | |
dc.identifier.citedreference | Onoue, S., Ohshima, K., Debari, K., Koh, K., Shioda, S., Iwasa, S., … Yajima, T. ( 2004 ). Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharmaceutical Research, 21 ( 7 ), 1274 – 1283. | |
dc.identifier.citedreference | O’Nuallain, B., & Wetzel, R. ( 2002 ). Conformational Abs recognizing a generic amyloid fibril epitope. Proceedings of the National Academy of Sciences of United States of America, 99 ( 3 ), 1485 – 1490. https://doi.org/10.1073/pnas.022662599 | |
dc.identifier.citedreference | Pedersen, J. S. ( 2010 ). The nature of amyloid‐like glucagon fibrils. Journal of Diabetes Science and Technology, 4 ( 6 ), 1357 – 1367. https://doi.org/10.1177/193229681000400609 | |
dc.identifier.citedreference | Pedersen, J. S., Dikov, D., Flink, J. L., Hjuler, H. A., Christiansen, G., & Otzen, D. E. ( 2006 ). The changing face of glucagon fibrillation: Structural polymorphism and conformational imprinting. Journal of Molecular Biology, 355 ( 3 ), 501 – 523. https://doi.org/10.1016/j.jmb.2005.09.100 | |
dc.identifier.citedreference | Wu, J. W., Breydo, L., Isas, J. M., Lee, J., Kuznetsov, Y. G., Langen, R., & Glabe, C. ( 2010 ). Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. Journal of Biological Chemistry, 285 ( 9 ), 6071 – 6079. https://doi.org/10.1074/jbc.M109.069542 | |
dc.identifier.citedreference | White, J. W., & Saunders, G. F. ( 1986 ). Structure of the human glucagon gene. Nucleic Acids Research, 14 ( 12 ), 4719 – 4730. | |
dc.identifier.citedreference | Ward, W. K., Massoud, R. G., Szybala, C. J., Engle, J. M., Youssef, J. E., Carroll, J. M., … DiMarchi, R. D. ( 2010 ). In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR‐D28) during aging: Lack of cytotoxicity and preservation of hyperglycemic effect. Journal of Diabetes Science and Technology, 4 ( 6 ), 1311 – 1321. https://doi.org/10.1177/193229681000400604 | |
dc.identifier.citedreference | Wang, W. ( 2005 ). Protein aggregation and its inhibition in biopharmaceutics. International Journal of Phamaceutics, 289 ( 1‐2 ), 1 – 30. https://doi.org/10.1016/j.ijpharm.2004.11.014 | |
dc.identifier.citedreference | Unson, C. G. ( 2002 ). Molecular determinants of glucagon receptor signaling. Biopolymers, 66 ( 4 ), 218 – 235. https://doi.org/10.1002/bip.10259 | |
dc.identifier.citedreference | Tiller, K. E., Chowdhury, R., Li, T., Ludwig, S. D., Sen, S., Maranas, C. D., & Tessier, P. M. ( 2017 ). Facile affinity maturation of antibody variable domains using natural diversity mutagenesis. Frontiers in Immunology, 8, 986. https://doi.org/10.3389/fimmu.2017.00986 | |
dc.identifier.citedreference | Tiller, K. E., Li, L., Kumar, S., Julian, M. C., Garde, S., & Tessier, P. M. ( 2017 ). Arginine mutations in antibody complementarity‐determining regions display context‐dependent affinity/specificity trade‐offs. Journal of Biological Chemistry, 292 ( 40 ), 16638 – 16652. https://doi.org/10.1074/jbc.M117.783837 | |
dc.identifier.citedreference | Steiner, S. S., Li, M., Hauser, R., & Pohl, R. ( 2010 ). Stabilized glucagon formulation for bihormonal pump use. Journal of Diabetes Science and Technology, 4 ( 6 ), 1332 – 1337. https://doi.org/10.1177/193229681000400606 | |
dc.identifier.citedreference | Shire, S. J. ( 2009 ). Formulation and manufacturability of biologics. Current Opinion in Biotechnology, 20 ( 6 ), 708 – 714. https://doi.org/10.1016/j.copbio.2009.10.006 | |
dc.identifier.citedreference | Russell, S. J., El‐Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., … Damiano, E. R. ( 2014 ). Outpatient glycemic control with a bionic pancreas in type 1 diabetes. New England Journal of Medicine, 371 ( 4 ), 313 – 325. https://doi.org/10.1056/NEJMoa1314474 | |
dc.identifier.citedreference | Russell, S. J., El‐Khatib, F. H., Nathan, D. M., Magyar, K. L., Jiang, J., & Damiano, E. R. ( 2012 ). Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care, 35 ( 11 ), 2148 – 2155. https://doi.org/10.2337/dc12‐0071 | |
dc.identifier.citedreference | Rabia, L. A., Zhang, Y., Ludwig, S. D., Julian, M. C., & Tessier, P. M. ( 2019 ). Net charge of antibody complementarity‐determining regions is a key predictor of specificity. Protein Engineering, Design and Selection. Advance online publication. https://doi.org/10.1093/protein/gzz002 | |
dc.identifier.citedreference | Pohl, R., Li, M., Krasner, A., & De Souza, E. ( 2015 ). Development of stable liquid glucagon formulations for use in artificial pancreas. Journal of Diabetes Science and Technology, 9 ( 1 ), 8 – 16. https://doi.org/10.1177/1932296814555541 | |
dc.identifier.citedreference | Albanell, J., & Baselga, J. ( 1999 ). Trastuzumab, a humanized anti‐HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today, 35 ( 12 ), 931 – 946. | |
dc.identifier.citedreference | Bakhtiani, P. A., Caputo, N., Castle, J. R., El Youssef, J., Carroll, J. M., David, L. L., … Ward, W. K. ( 2015 ). A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. Journal of Diabetes Science and Technology, 9 ( 1 ), 17 – 23. https://doi.org/10.1177/1932296814552476 | |
dc.identifier.citedreference | Castle, J. R., Engle, J. M., El Youssef, J., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. ( 2010 ). Novel use of glucagon in a closed‐loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care, 33 ( 6 ), 1282 – 1287. https://doi.org/10.2337/dc09‐2254 | |
dc.identifier.citedreference | Chabenne, J. R., DiMarchi, M. A., Gelfanov, V. M., & DiMarchi, R. D. ( 2010 ). Optimization of the native glucagon sequence for medicinal purposes. Journal of Diabetes Science and Technology, 4 ( 6 ), 1322 – 1331. https://doi.org/10.1177/193229681000400605 | |
dc.identifier.citedreference | De Jong, K. L., Incledon, B., Yip, C. M., & DeFelippis, M. R. ( 2006 ). Amyloid fibrils of glucagon characterized by high‐resolution atomic force microscopy. Biophysical Journal, 91 ( 5 ), 1905 – 1914. https://doi.org/10.1529/biophysj.105.077438 | |
dc.identifier.citedreference | Dobson, C. M. ( 1999 ). Protein misfolding, evolution and disease. Trends in Biochemical Sciences, 24 ( 9 ), 329 – 332. | |
dc.identifier.citedreference | Dong, M., Hovgaard, M. B., Xu, S., Otzen, D. E., & Besenbacher, F. ( 2006 ). AFM study of glucagon fibrillation via oligomeric structures resulting in interwoven fibrils. Nanotechnology, 17 ( 16 ), 4003 – 4009. https://doi.org/10.1088/0957‐4484/17/16/001 | |
dc.identifier.citedreference | El‐Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. ( 2010 ). A bihormonal closed‐loop artificial pancreas for type 1 diabetes. Science Translational Medicine, 2 ( 27 ), 27ra27. https://doi.org/10.1126/scitranslmed.3000619 | |
dc.identifier.citedreference | Falk, R., Falk, A., Dyson, M. R., Melidoni, A. N., Parthiban, K., Young, J. L., … McCafferty, J. ( 2012 ). Generation of anti‐Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods, 58 ( 1 ), 69 – 78. https://doi.org/10.1016/j.ymeth.2012.07.008 | |
dc.identifier.citedreference | Ghodke, S., Nielsen, S. B., Christiansen, G., Hjuler, H. A., Flink, J., & Otzen, D. ( 2012 ). Mapping out the multistage fibrillation of glucagon. FEBS Journal, 279 ( 5 ), 752 – 765. https://doi.org/10.1111/j.1742‐4658.2011.08465.x | |
dc.identifier.citedreference | Gratzer, W. B., Bailey, E., & Beaven, G. H. ( 1967 ). Conformational states of glucagon. Biochemical and Biophysical Research Communications, 28 ( 6 ), 914 – 919. | |
dc.identifier.citedreference | Hall‐Boyer, K., Zaloga, G. P., & Chernow, B. ( 1984 ). Glucagon: Hormone or therapeutic agent? Critical Care Medicine, 12 ( 7 ), 584 – 589. | |
dc.identifier.citedreference | Hovgaard, M. B., Dong, M., Otzen, D. E., & Besenbacher, F. ( 2007 ). Quartz crystal microbalance studies of multilayer glucagon fibrillation at the solid‐liquid interface. Biophysical Journal, 93 ( 6 ), 2162 – 2169. https://doi.org/10.1529/biophysj.107.109686 | |
dc.identifier.citedreference | Hrncic, R., Wall, J., Wolfenbarger, D. A., Murphy, C. L., Schell, M., Weiss, D. T., & Solomon, A. ( 2000 ). Antibody‐mediated resolution of light chain‐associated amyloid deposits. American Journal of Pathology, 157 ( 4 ), 1239 – 1246. https://doi.org/10.1016/S0002‐9440(10)64639‐1 | |
dc.identifier.citedreference | Isas, J. M., Luibl, V., Johnson, L. V., Kayed, R., Wetzel, R., Glabe, C. G., … Chen, J. ( 2010 ). Soluble and mature amyloid fibrils in drusen deposits. Investigative Ophthalmology and Visual Science, 51 ( 3 ), 1304 – 1310. https://doi.org/10.1167/iovs.09‐4207 | |
dc.identifier.citedreference | Julian, M. C., Rabia, L. A., Desai, A. A., Arsiwala, A., Gerson, J. E., Paulson, H. L., … Tessier, P. M. ( 2019 ). Nature‐inspired design and evolution of anti‐amyloid antibodies. Journal of Biological Chemistry. Advance online publication. https://doi.org/10.1074/jbc.RA118.004731 | |
dc.identifier.citedreference | Kayed, R., & Glabe, C. G. ( 2006 ). Conformation‐dependent anti‐amyloid oligomer antibodies. Methods in Enzymology, 413, 326 – 344. https://doi.org/10.1016/S0076‐6879(06)13017‐7 | |
dc.identifier.citedreference | Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. ( 2003 ). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300 ( 5618 ), 486 – 489. https://doi.org/10.1126/science.1079469 | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.